Clinical Trials
11 trialsNCT03934372 2026-04-16
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
Phase 1/2 Recruiting
NCT02467270 2026-03-17
OPTIC
Takeda
Phase 2 Completed
NCT03589326 2025-11-26
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Takeda
Phase 3 Active not recruiting
NCT04233346 2025-04-04
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
Otsuka Beijing Research Institute
Phase 2 Active not recruiting
NCT01667133 2022-06-13
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Takeda
Phase 1/2 Completed
NCT01641107 2021-11-30
LAL1811
Incyte Corporation
Phase 2 Completed
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT01207440 2021-02-02
PACE
Takeda
Phase 2 Completed
NCT01874665 2018-05-18
GIST
Takeda
Phase 2 Completed
NCT00660920 2018-05-16
Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
Takeda
Phase 1 Completed
NCT01650805 2014-11-17
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
Phase 3 Terminated